According to a new study, the amino acid valine, a chemical building element of many animal proteins, is involved in malignant growth in T cell acute lymphoblastic leukaemia.
The research has been published in the ‘Nature Journal’.
Led by researchers at NYU Langone Health, its Department of Pathology, and the Laura and Isaac Perlmutter Cancer Center, the study showed that genes involved in using up valine in cells were more active in cancerous T cells than in normal T cells.
Blocking these valine-linked genes not only led to decreased valine in leukaemia blood T cells but also stalled these tumour cells from growing in the lab. Only 2 per cent of cancerous T cells remained alive.
Further, experiments suggested that changes (mutations) in the DNA code of the gene NOTCH1, the most commonly seen in patients who develop leukaemia, encouraged cancer growth in part by increasing valine levels.
The research involved experiments in human leukaemia cells grown in the lab and also transplanted into mice that then develop this cancer, which has its origins in white blood cells in the bone marrow.
Further experiments showed that feeding the leukemic mice low-valine diets for three weeks interrupted tumour growth. The diet also reduced circulating blood cancer cells by at least half and in some cases to undetectable levels. By contrast, the re-introduction of valine to the diets led to cancer progression.
“Our study confirms that T cell acute lymphoblastic leukaemia is absolutely dependent on a supply of valine and that valine deficiency can stall this cancer’s progression,” said study co-lead investigator Palaniraja Thandapani, PhD, a postdoctoral fellow at NYU Grossman School of Medicine and its Perlmutter Cancer Center.
The research team has planned next year to test whether diets low in valine-rich foods, such as meat, fish, and beans, are an effective treatment in people with cancer. Low-valine diets are readily available, Thandapani said, as they are already being used to treat acid imbalances in the body tied to genetic disorders that affect gut metabolism.
Senior study investigator Iannis Aifantis, PhD, said that the trial design would likely combine diet therapy with venetoclax, a drug already approved for use in the United States for most other types of leukaemia.
The drug combination is important, he said, because such dietary restrictions are not likely sustainable in the long term. This is due to the known potential for muscle wasting and brain damage from prolonged valine deficiency.
“Our clinical approach would involve using low-valine diets to shrink the number of T cells with acute lymphoblastic leukaemia to a level so low that drugs could then effectively stall cancer progression,” said Aifantis, the Hermann M. Biggs Professor and chair of the Department of Pathology at NYU Grossman and Perlmutter.
Aifantis said many basic cell building blocks, including proteins, nucleotides, and fatty acids, are needed for cancer to grow and spread. At least half a dozen other amino acids, especially high levels of lysine, have been implicated in cancers, but their precise roles remain unknown. He cautioned that dietary strategies alone for treating cancer have been tried for decades with little scientific evidence of any benefit. He said more research is needed, including the team’s planned clinical trial, before any treatment guidelines can be recommended.
The American Cancer Society estimated that more than 1,500 Americans, mostly children, die each year from T cell acute lymphoblastic leukaemia. Another 5,000 will be newly diagnosed. This type of cancer accounts for roughly one-quarter of all leukaemias.
Funding support for the study was provided by National Institutes of Health grants P30CA016087, P01 CA229086 and R01 CA228135; the Leukemia & Lymphoma Society; New York State Department of Health’s Study finds nutrient’s role in childhood blood cancerNYSTEM program; and the American Association for Cancer Research Incyte Corporation Leukemia Research Fellowship.
Besides Thandapani, Aifantis and Tsirigos, other NYU Langone researchers involved in the study co-lead investigators Andreas Kloetgen; Matthew Witkowski; and Christina Glytsou; and study co-investigators Anna Lee; Eric Wang, Jingjing Wang; Sarah LeBoeuf; Kleopatra Avrampou; and Thales Papagiannakopoulos.
